Tag Archives: blockbuster

Vertex lands blockbuster triple combo nod for CF drug Trikafta—5 months early

The triple combo era in cystic fibrosis is here thanks to a Monday Vertex approval—and it’s here earlier than industry watchers expected. A lot earlier. Five months ahead of schedule—and just three months after the company submitted its regulatory application—the FDA green-lighted Trikafta for the treatment of CF patients over the age of 12 with… Read More »

Novartis has its blockbuster Beovu OK, but its ‘hot mess’ label leaves something to be desired: analysts

Novartis has big plans for its new wet age-related macular degeneration drug Beovu, but as some doctors and analysts see it, the company has an uphill climb thanks to uncertainties and shortcomings in the med’s label.  After holding a call with a key opinion leader, SVB Leerink analyst Geoffrey Porges wrote that the “lack of clarity” about Beovu’s dosing schedule will serve as one… Read More »

J&J’s Darzalex pads blockbuster sales with another myeloma nod in new patients

Johnson & Johnson multiple myeloma drug Darzalex hasn’t stopped rolling since hitting the market. After picking up its first nod in previously untreated patients last May, the drug added a second indication in new patients on Thursday—and its sixth overall. The FDA cleared the product in combination with Celgene’s Revlimid and dexamethasone for patients who… Read More »

Array’s ‘extremely compelling’ new colon cancer data spark blockbuster talk

The news that Array BioPharma’s clinical trial of its triplet therapy for colon cancer extended lives in a trial of patients with the BRAF mutation sent the company’s shares up 23% on Tuesday—a run that was no doubt driven by hopes the therapy will eventually be adopted as the standard of care in that population.… Read More »